Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy

Neuropharmacology

Volumn 58, Issue 3, 2010, Pages 585-592

  Negi, Geeta ^a   Kumar, Ashutosh ^a   Kaundal, Ravinder K ^a   Gulati, Anil ^b   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Diabetic neuropathy; Melatonin; MNCV; NBF; Nicotinamide; Oxidative stress; PARP

Indexed keywords

3 NITROTYROSINE; GLUCOSE; MELATONIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXYNITRITE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MONOTHERAPY; MOTOR NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PAIN PARAMETERS; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; TREATMENT DURATION;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPERALGESIA; LIPID PEROXIDATION; MALE; MELATONIN; NEURAL CONDUCTION; NIACINAMIDE; PAIN MEASUREMENT; PAIN THRESHOLD; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; SCIATIC NERVE; STREPTOZOCIN; TYROSINE; VITAMIN B COMPLEX;

EID: 73449142425     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.11.018     Document Type: Article

References (36)

1. Anwar M.M., and Meki A.R.M. Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin. Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 135 (2003) 539-547
2. Arora M., Kumar A., Kaundal R.K., and Sharma S.S. Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimental diabetic neuropathy. Eur. J. Pharmacol. 596 (2008) 77-83
3. Arreola-Espino R., Urquiza-Marín H., Ambriz-Tututi M., Araiza-Saldaña C.I., Caram-Salas N.L., Rocha-González H.I., Mixcoatl-Zecuatl T., and Granados-Soto V. Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur. J. Pharmacol. 577 (2007) 203-210
4. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., Salvemini D., and Yorek M.A. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br. J. Pharmacol. 134 (2001) 21-29
5. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., and Yorek M.A. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50 (2001) 1927-1937
6. Derlacz R.A., Poplawski P., Napierala M., Jagielski A.K., and Bryla J. Melatonin-induced modulation of glucose metabolism in primary cultures of rabbit kidney-cortex tubules. J. Pineal Res. 38 (2005) 164-169
7. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112 (2003) 1049-1057
8. Guven A., Yavuz O., Cam M., Ercan F., Bukan N., Comunoglu C., and Gokce F. Effects of melatonin on streptozotocin-induced diabetic liver injury in rats. Acta Histochem. 108 (2006) 85-93
9. Hassa P.O., and Hottiger M.O. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol. Life Sci. 59 (2002) 1534-1553
10. Hoeldtke R.D., Bryner K.D., McNeill D.R., Hobbs G.R., Riggs J.E., Warehime S.S., Christie I., Ganser G., and Van Dyke K. Nitrosative stress, uric acid, and peripheral nerve function in early type1 diabetes. Diabetes 51 (2002) 2817-2825
11. Ilnytska O., Lyzogubov V.V., Stevens M.J., Drel V.R., Mashtalir N., Pacher P., Yorek M.A., and Obrosova I.G. Poly(ADP-Ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55 (2006) 1686-1694
12. Kameoka M., Ota K., Tetsuka T., Tanaka Y., Itaya A., Okamoto T., and Yoshihara K. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem. J. 346 Pt 3 (2000) 641-649
13. Kanter M., Uysal H., Karaca T., and Sagmanligil H.O. Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats. Arch. Toxicol. 80 (2006) 362-369
14. Kumar A., Kaundal R.K., Iyer S., and Sharma S.S. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 80 (2007) 1236-1244
15. Li F., Drel V.R., Szabo C., Stevens M.J., and Obrosova I.G. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 54 (2005) 1514-1522
16. Loetscher P., Alvarez-Gonzalez R., and Althaus F.R. Poly(ADP-ribose) may signal changing metabolic conditions to the chromatin of mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 1286-1289
17. Mabley J.G., and Soriano F.G. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction. Curr. Vasc. Pharmacol. 3 (2005) 247-252
18. Negi, G., Kumar, A., Sharma, S.S. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun., in press. doi:10.1016/j.bbrc.2009.11.010.
19. Nisselbaum J.S., and Green S. A simple ultramicro method for determination of pyridine nucleotides in tissue. Anal. Biochem. 27 (1969) 212-217
20. Obrosova I.G. Peroxynitrite and cardiomyocyte cell death: an evolving story. A commentary on "Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo". Free Radic. Biol. Med. 41 (2006) 866-868
21. Obrosova I.G., Drel V.R., Pacher P., Ilnytska O., Wang Z.Q., Stevens M.J., and Yorek M.A. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54 (2005) 3435-3441
22. Obrosova I.G., Li F., Abatan O.I., Forsell M.A., Komjati K., Pacher P., Szabo C., and Stevens M.J. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53 (2004) 711-720
23. Obrosova I.G., Xu W., Lyzogubov V.V., Ilnytska O., Mashtalir N., Vareniuk I., Pavlov I.A., Zhang J., Slusher B., and Drel V.R. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic. Biol. Med. 44 (2008) 972-981
24. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
25. Sánchez-Fidalgo S., Villegas I., Martín A., Sánchez-Hidalgo M., and Alarcón de la Lastra C. PARP inhibition reduces acute colonic inflammation in rats. Eur. J. Pharmacol. 563 (2007) 216-223
26. Sayyed S.G., Kumar A., and Sharma S.S. Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci. 79 (2006) 777-783
27. Schmeichel A.M., Schmelzer J.D., and Low P.A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52 (2003) 165-171
28. Sharma S.S., Kumar A., Arora M., and Kaundal R.K. Neuroprotective potential of combination of resveratrol and 4-amino1,8 naphthalimide in experimental diabetic neuropathy: focus on functional, sensorimotor and biochemical changes. Free Radic. Res. 43 (2009) 400-408
29. Sharma S.S., Kumar A., and Kaundal R.K. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci. 82 (2008) 570-576
30. Srivastava S.K., Ramana K.V., and Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26 (2005) 380-392
31. Stevens M.J., Li F., Drel V.R., Abatan O.I., Kim H., Burnett D., Larkin D., and Obrosova I.G. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J. Pharmacol. Exp. Ther. 320 (2007) 458-464
32. Sudnikosh E.J., Maksimchik Y.J., Zabrodekaya S.V., Kubyshim V.L., Bryszewska M., Reiter R.J., and Zovodnik I.B. Melatonin attenuates metabolic disorders due to streptozotocin induced diabetes in rats. Eur. J. Pharmacol. 569 (2007) 180-187
33. Sugimoto K., Yasujima M., and Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 14 (2008) 953-961
34. Vincent A.M., Edwards J.L., Sadidi M., and Feldman E.L. The antioxidant response as a drug target in diabetic neuropathy. Curr. Drug Targets 9 (2008) 94-100
35. Yamagishi S., Ogasawara S., Mizukami H., Yajima N., Wada R., Sugawara A., and Yagihashi S. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J. Neurochem. 104 (2008) 491-499
36. Yang J., Klaidman L.K., Nalbandian A., Oliver J., Chang M.L., Chan P.H., and Adams Jr. J.D. The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats. Neurosci. Lett. 333 (2002) 91-94